that are interconnected and highly integrated, with each system 139 being autoregulatory while also modulating the activities of the 140 f3 others (Figure 3 ). The las system for example positively controls 141 both rhl and pqs system genes that code for QSSM receptors 142 (rhlR and pqsR) and synthase genes (rhlI and pqsH). However, 143 while some target genes are specifically regulated by las and 144 others by rhl, some require both of these QS systems for full 145 activation. 29 The las and rhl systems rely on two different N-acyl- 206 reporter strain with IC 50 values of 16.1 and 14.8 μM, 207 respectively. 36 In a later study, the same group of researchers 208 expanded the SAR of these inhibitors and submicromolar 209 antagonists were identified using an E. coli reporter strain (9, 210 1.72 μM; 10, 610 nM; 11, 250 nM; 12, 340 nM). 37 Similar 211 structures have also been published as LasR antagonists with 212 IC 50 values of 1 and 10 μM for 13 and 14, respectively. 38 213 Although Jadhav et al. focused on the structure−activity 214 relationship of 3OC12-HSL analogs as immune modulators, a 215 series of LasR antagonists was found bearing modifications of 216 the hydrophobic tail region. The compounds were screened 217 using a native P. aeruginosa reporter assay at 100 μM ligand 218 concentration to reveal that 15 and 16 had reduced the activity 219 of LasR to less than 6%. 39 Triazole-derived tail structures were In an E. coli based reporter assay, 48 showed a 365 concentration-dependent inhibition with an IC 50 of 4.8 μM and 366 was able to reduce pyocyanin production and biofilm formation 367 in P. aeruginosa. 69 368 ■ LasI INHIBITORS 369 LasI, the 3OC12-HSL synthase, has received less attention as a 370 target for disrupting the las-dependent QS. There appears to be f8 371 only one report describing 49 ( Figure 8 ) as a LasI inhibitor 372 (∼40% inhibition at 20 μM) in a heterologous E. coli-based 373 reporter strain causing a significant reduction in biofilm and 374 swarming motility. A microarray-based transcriptomic assay 375 revealed that lasI along with the pqsABCDE genes were down-376 regulated after treatment with 49 compared to the untreated 377 cells, a result that would be expected given that LasR/3OC12-378 HSL is involved in regulating both AHL and AQ biosynthesis in 379 P. aeruginosa ( Figure 3 ). 70
The P. aeruginosa rhl system employs 2 N-butanoyl-L-383 homoserine lactone (C4-HSL) and is responsible for the 384 expression of multiple virulence factors including rhamnolipids, 385 HCN, swarming motility and contributes to biofilm maturation. 386 The expression of the rhl system is controlled by the las system 387 as the LasR/3OC12-HSL complex activates the transcription of 388 both rhlR and rhlI leading to more C4-HSL and the activation of 389 a wide range of RhlR/C4-HSL controlled genes. The rhl QS 390 system has received less attention compared with the las system 391 as most published work has focused on the latter probably due to 392 its location at the top of the P. aeruginosa QS hierarchy. Hence it 393 remains unclear as to whether RhlI and RhlR both represent a 394 valid drug discovery target especially since a rhlI mutant in 395 contrast to a rhlR mutant retains full virulence in a mouse 396 infection model. 71
f9
The RhlR modulator 50 ( Figure 9 ) was reported to act as an 398 antagonist in the presence of C4-HSL and an agonist in its 399 absence. 50 reduced pyocyanin production (IC 50 = 8 μM), The P. aeruginosa pqs QS system relies on 2-alkyl-4-quinolone 455 signal molecules rather than AHLs that interact with their (Figure 3 and Figure 10 ). P. aeruginosa produces a 460 diverse range of over 50 AQ molecules of three main classes, 2-461 alkyl-4-hydroxyquinolines, 2-alkyl-3-hydroxy-4-quinolones, and 462 2-alkyl-4-hydroxyquinoline-N-oxides including HHQ 3 (2-463 heptyl-4-hydroxyquinolone), and the Pseudomonas quinolone 464 signal 4 (PQS) (2-heptyl-3-hydroxy-4(1H)-quinolone). PQS/ 465 HHQ and their C-9 congeners are all able to activate PqsR. In 466 contrast to HHQ, PQS is an iron chelator and regulates the 467 expression of genes involved in the iron-starvation response and 468 virulence factor production via both PqsR-dependent and PqsR-469 independent pathways. 94,95 AQ biosynthesis is achieved via the 470 condensation of 70 and β-keto fatty acids mediated by the 471 heterodimeric enzyme PqsBC to afford HHQ which can be 472 hydroxylated at the 3-position via PqsH to yield PQS. 96 although only 22% of these were to promoter regions. 104 Most of 
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Perspective 500 the binding sites were located inside a gene or overlapping 501 several genes, and hence their functionality as PqsR binding sites 502 remains to be validated. 104 (Figure 11 ; 73, IC 50 = 51 nM; 74, IC 50 = 54 nM) at the 6-512 position of the HHQ quinoline ring. Despite the fact that these 513 compounds showed good potency using the E. coli reporter, in P. 514 aeruginosa, only a modest reduction in pyocyanin was noted and 515 they failed to reduce elastase, rhamnolipids, or AQ levels. 105,106 516 When 73 and 74 were further tested in P. aeruginosa, it became 517 clear that PqsH-mediated the oxidation at the 3-position of the 518 quinoline ring of these inhibitors converting them to potent 519 agonists. This effect was not observed for compound 75 (IC 50 = 520 35 nM, E. coli reporter, IC 50 = 4 μM, P. aeruginosa reporter) 521 where a blocking group (CONH 2 ) was introduced at the 3-522 position to preserve the antagonistic activity in P. aerugino-523 sa. 107−109 Klein et al. reported another series of weak PqsR 524 inhibitors derived from N-hydroxybenzamides with modifica-525 tion at the para-position. Only modest activity against PqsR was 526 attained with 76 (IC 50 in E. coli of 12.5 μM vs IC 50 in P. 527 aeruginosa of 23.6 μM) which weakly affected pyocyanin at IC 50 528 concentrations. 110 In a follow-up study, the carboxamide group 529 was replaced by a 1,3,4-oxadiazole moiety to provide 77 with 530 similar antagonist activity to 76 along with marginal activity on 531 pyocyanin and AQ production. Figure 12A highlights the hydrophobic residues surrounding pocket B. Figure 12B shows the binding pose of heterocyclic headgroup residing in pocket A. The poses were generated using Maestro, Schrodinger, LLC, New York, NY (2018). 
Perspective 745 its essential components including crystal structures for PqsR, 746 PqsA, PqsD, PqsBC, and PqsE, it is clear that certain elements of 747 the pqs system represent attractive drug discovery targets. 748 Indeed, inhibitors 80 and 81 have advanced in preclinical stages 749 and the available data provide a robust proof of concept for 750 targeting PqsR. PqsA, PqsD are emerging as additional new 751 targets that have yet to be fully explored. Despite the fact that the 752 PqsBC heterodimer is critical for AQ biosynthesis, its validity as 753 antivirulence targets remains to be elucidated. The lack of 754 attenuation of pqsE mutants in mouse infection models indicates 755 that PqsE is unlikely to be a good target. The asterisk ( * ) indicates that these parameters were predicted using Instant JChem 18.8.0, 2018, ChemAxon (http://www.chemaxon.com). There are few reports describing the development of 767 resistance to QSIs in P. aeruginosa. For the furanone-derived 768 compound 27, the underlying resistance mechanism was solely 769 reasoned to the up-regulation of an efflux pump due to a 770 mutation in mexR and nalC regulatory genes. 148,149 However, it 771 is noteworthy that the QSI concentration used for this study was 772 at least 25-fold higher than that previously reported for QS 773 inhibition by 26 in the original literature. At such elevated 774 concentrations, 26 is cytotoxic and growth inhibitory and so will 775 exert selective pressures on the bacteria to drive the evolution of 776 mutations that confer resistance. 777 Currently, the literature relating to QSI resistance is scarce 778 and limited to certain cases and specific growth conditions. 779 Further investigations of selection for QSI resistance in 780 conditions that mimic in vivo infections will be vital to establish 781 a sound platform for the future design and development of QSIs 782 with nanomolar potencies. 783 ■ CONCLUSION 784 Through reviewing the medicinal chemistry related QS 785 literature, it is clear that more effort needs to be directed toward 786 the design of drug-like molecules with favorable physiochemical 787 properties. It becomes evident that the majority of the inhibitors 788 identified to date function as useful probes for mechanistic 789 studies rather than lead-like compounds for further drug t2 790 development as summarized in Table 2 . 791 In addition, the lack of methodological standardization in 792 assessing QSI candidates including the use of single laboratory-793 adapted P. aeruginosa strains limits the broad validity of any 794 findings such that these may be distant from relevant clinical 795 infections and so constitute a major pitfall in this field. Within 796 the P. aeruginosa QS circuitry, the pqs system holds promise for 797 prospective therapeutics particularly at the level of PqsR where 798 inhibitors with nanomolar potencies and lead-like properties 799 have already been developed. However, it is important to note 800 that QS inhibitors are most likely to be beneficial as adjuvants for 801 conventional antibiotics rather than as standalone therapeutic 802 agents, although they may prove useful for prophylaxis. 803 Undoubtedly, polypharmacology through the concurrent use 804 of inhibitors for various targets/QS systems could also prove 805 highly beneficial in combating multiantibiotic bacterial resist-806 ance. 
